P3 Health Partners Earnings Call Highlights Growth, Profitability

P3 Health Partners (PIII) reported Q3 earnings with 15% revenue growth, $21M Adjusted EBITDA, and raised 2026 guidance to $90M-$110M. Challenges include higher outpatient costs and lower at-risk membership. Management highlighted medical-cost control, quality gains, and expansion plans.

Original reporting
Published Nov 15, 2026, 2:24 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 15, 2026, 9:13 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$PIII
Bullish
high confidence
Mentioned
$PIII
Relevance
7/10
AlphAI data visualization · based on tipranks.com
Decision brief

The 30-second read

$PIIIBullishMed
01

Why it matters

The earnings beat and guidance raise are likely to drive short‑term price appreciation, though cost pressures remain a risk.

02

Market read

Earnings beat and guidance raise make the stock a near‑term candidate for buying on momentum.

03

What to watch

Rising Nevada costs and at‑risk membership decline could offset upside.

Relevance 7/10Novelty 7/10Timing: after-hours today

Background

P3 Health Partners reported Q3 results with revenue up 15% YoY and lifted its 2026 EBITDA guidance.

Company-level read

Ticker impact

$PIIIBullishHigh confidence
Context

Q3 earnings call disclosed 15% revenue growth, $21M Adjusted EBITDA and raised full-year guidance to $90M-$110M.

Expected impact

likely upward pressure as market prices in higher earnings outlook

Evidence & confidence

Management highlighted three consecutive profitable quarters and lifted the EBITDA midpoint, which typically supports a price rally.

Market effects

Positive earnings may boost sentiment in the Medicare Advantage and health services sector.

U.S. healthcare stocks could see modest gains.

Limited to U.S. health‑care investors.

Counterpoint

Guidance raise may already be priced in; watch for higher outpatient cost pressure.

Key entities

  • P3 Health Partners Inc.

    Provider of Medicare Advantage services.

Related articles

$PIIIMed

P3 Health (PIII) Q3 2026 Earnings Call Transcript

P3 Health (PIII) reported Q3 2026 Adjusted EBITDA of $21M, raising full-year guidance to $90M-$100M. CEO Aric Coffman highlighted medical cost management, quality improvements, and growth strategies. The company is expanding in existing markets and entering new ones, like Nebraska, with a capital-efficient approach.

$PIIIMed

P3 Health Partners Announces Third Quarter 2026 Results

P3 Health Partners Inc. (PIII) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 P3 Health Partners Announces Third Quarter 2026 Results Adjusted EBITDA of $21 Million for the Third Quarter and $101 Million Year-to-Date Raises Full-Year 2026 Adjusted EBITDA Guidance Midpoint Management to Host Conference Call and Webcast November 9, 2026 at 4:30

$PIIIMedAI 9/10

P3 Health Partners (PIII) Q2 2026 Earnings Call Transcript

P3 Health Partners (PIII) reported Q2 2026 adjusted EBITDA of $54.4 million versus a prior-year loss, on total revenue of $386.4 million (+9% YoY). At-risk membership fell 10% to 105,000. Net income was $15.7 million. The company raised full-year 2026 guidance to adjusted EBITDA of $80 million to $110 million and revenue of $1.5 billion to $1.6 billion.